Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

5.6%

22 terminated/withdrawn out of 396 trials

Success Rate

67.2%

-19.3% vs industry average

Late-Stage Pipeline

8%

30 trials in Phase 3/4

Results Transparency

0%

0 of 45 completed trials have results

Key Signals

173 recruiting12 terminated10 withdrawn

Enrollment Performance

Analytics

Phase 2
151(42.9%)
Phase 1
84(23.9%)
N/A
62(17.6%)
Early Phase 1
25(7.1%)
Phase 4
19(5.4%)
Phase 3
11(3.1%)
352Total
Phase 2(151)
Phase 1(84)
N/A(62)
Early Phase 1(25)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (396)

Showing 20 of 396 trials
NCT07644481Not ApplicableNot Yet Recruiting

Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission

Role: lead

NCT07644026Not Yet Recruiting

HBV Reactivation Prediction Model in Allo-HSCT

Role: collaborator

NCT07643103Phase 2Not Yet Recruiting

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

Role: lead

NCT06594640Phase 1Recruiting

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Role: lead

NCT07315503Early Phase 1Withdrawn

An Open-label Study of GC012F in Rheumatoid Arthritis.

Role: lead

NCT07555470Phase 2Recruiting

Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma

Role: lead

NCT07490275Phase 1Not Yet Recruiting

Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT07490288Not ApplicableRecruiting

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

Role: lead

NCT05850286Phase 2Active Not Recruiting

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Role: lead

NCT07205315Early Phase 1Recruiting

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Role: collaborator

NCT07588945Phase 3Not Yet Recruiting

daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

Role: lead

NCT07585734Phase 1Withdrawn

Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia

Role: lead

NCT07585747Phase 2Not Yet Recruiting

A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

Role: lead

NCT07585760Phase 2Recruiting

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment

Role: lead

NCT06611839Phase 1Recruiting

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Role: lead

NCT06116318Withdrawn

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

Role: lead

NCT06744556Phase 2Active Not Recruiting

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

Role: lead

NCT07299149Phase 2Recruiting

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

Role: lead

NCT06561880Phase 1Recruiting

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Role: lead

NCT07493161Not ApplicableRecruiting

Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

Role: lead